


SYNTHESIS OF MULTI RING-FUSED PEPTIDOMIMETICS INTERACTING WITH α -SYNUCLEIN FIBRILS

Dan E. Adolfsson, Pardeep Singh, Jörgen Ådén, Mohit Tyagi, Andrew G. Cairns, Christian Bartens, Adrian Deuchmann and Fredrik Almqvist


Department of Chemistry, Umeå University, 901 87 Umeå, Sweden

The Thiazolino ring-fused 2-pyridone scaffolds were initially developed as peptidomimetics to inhibit the production of pili in uropathogenic *E.coli* [1]. When the scaffold was later equipped with other substituents, it gained the ability to modulate the formation of amyloid fibers, such as fibers of α -synuclein, whose formation *in vivo* is associated with Parkinson's disease [2] in humans.

In a recent publication we described the synthesis of fluorescent ring-fused 2-pyridones with five fused rings (**1**) and an extended peptidomimetic backbone that modulates the aggregation of α -synuclein *in vitro* [3]. We subsequently constructed a tricyclic pyridine fused 2-pyridone scaffold (**2**) whereof several examples showed α -synuclein binding by ThT displacement *in vitro* [4]. Initial evaluations of one such compound in mice moreover indicated a protective effect against accelerator-induced neurodegeneration, when injected 14 days prior to the aggregation accelerator FN075 [2]. This observation was further consolidated when protection of TH-positive neuron cells, from cell death caused by the same accelerator, was demonstrated.



The assembly of our pyridine-fused heterocycles rely on the three-component Povarov reaction. Aware of the possibility to perform the Povarov reaction in an intramolecular fashion, we envisioned a modified scaffold with increased hydrophilicity (**3**). We have further noticed by aims-test that our modified scaffold showed no mutagenicity. Gratifyingly, examples of the modified scaffold showed retained affinity to α -synuclein fibrils, demonstrated by loss of fluorescence upon ThT displacement. Informative SAR was revealed and further synthesis and evaluation is on-going.



Scheme 1: Synthesis of non-mutagenic amyloid binding peptidomimetic **3** with improved hydrophilicity and stability.

[1] a) Pinkner, J. S. et al. Proc. Natl. Acad. Sci. USA 2006, 103 (47) 17897–17902.

b) Chorell, E. et al., J. Med. Chem. 2010, 53 (15), 5690–5695.

[2] a) Horvath, I. et al., J. Am. Chem. Soc. 2012, 134, 3439–3444.

b) Cegelski, L. et al., Nat. Chem. Biol., 2009, 5, 913–919.

[3] Singh, P. et al., Org. Lett. 2015, 17 (24), 6194–6197.

[4] Singh, P. et al., J. Org. Chem. 2019, DOI: 10.1021/acs.joc.8b03015.